Imexpharm

Imexpharm EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Imexpharm (IMP.VN) as of Oct 26, 2026 is 3.46. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 3.77 — a change of -8.29% (lower).

EV/Revenue

3.46

YoY

-8.29%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Imexpharm is 2025 3.46 . EV/Revenue (Enterprise Value to Revenue) of Imexpharm was 2024 3.77 . It decreases by -8.29% lower compared to the previous year.

The Imexpharm EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2018
6.78 VND
Jan 1, 2019
5.89 VND
Jan 1, 2020
6.10 VND
Jan 1, 2021
6.70 VND
Jan 1, 2022
5.06 VND
Jan 1, 2023
4.15 VND
Jan 1, 2024
3.77 VND
Jan 1, 2025
3.46 VND
The Imexpharm EV/Revenue history
YEAREV/RevenueYoY
3.46-8.29%
3.77-9.17%
4.15-18.02%
5.06-24.48%
6.70+9.84%
6.10+3.57%
5.89-13.07%
6.78-0.46%
6.81-15.17%
8.03-3.65%
8.33-7.08%
8.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

EV/Revenue (Enterprise Value to Revenue) of Imexpharm is 3.46 in 2025.

EV/Revenue (Enterprise Value to Revenue) of Imexpharm changed from 3.77 to 3.46, representing a -8.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Imexpharm since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Imexpharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Imexpharm

All Key Metrics — Imexpharm